You are viewing the site in preview mode
Skip to main content
| |
LMF oil
|
Placebo oil
|
Treatment effect (95% CI)
|
|---|
| |
N
|
Value
|
Adjusted mean changeb
|
N
|
Value
|
Adjusted mean changeb
|
|---|
|
Changes in hemoglobin (Hb) levels, gm%
|
|
Hb at 6 months
|
199
|
10.84 ± 0.88
|
−0.50
|
204
|
10.96 ± 0.90
|
− 0.54
|
− 0.01(− 0.26–0.28)
|
|
Hb at 12 months
|
190
|
10.36 ± 1.26
|
201
|
10.42 ± 1.30
|
|
Subgroup of children with no anemia (Hb > 11 g%) at 6 monthse
|
|
Hb at 6 months
|
88
|
11.61 ± 0.41
|
−0.70
|
101
|
11.68 ± 0.55
|
− 0.62
|
−0.08(− 0.38–0.23)
|
|
Hb at 12 months
|
84
|
10.90 ± 1.03
|
99
|
11.05 ± 1.09
|
|
Subgroup of children with mild anemia (Hb 10–11 g%) at 6 monthse
|
|
Hb at 6 months
|
85
|
10.51 ± 0.28
|
−0.44
|
77
|
10.52 ± 0.32
|
− 0.41
|
−0.03(− 0.37–0.31)
|
|
Hb at 12 months
|
84
|
10.08 ± 1.23
|
76
|
10.08 ± 1.10
|
|
Subgroup of children with moderate anemia(Hb 7- < 10 g%) at 6 monthse
|
|
Hb at 6 months
|
26
|
9.31 ± 0.56
|
0.11
|
26
|
9.49 ± 0.33
|
− 0.51
|
0.62(0.02–1.22)c
|
|
Hb at 12 months
|
22
|
9.34 ± 1.26
|
26
|
8.98 ± 1.04
|
|
Changes in transferrin saturation (TSAT) levels, %
|
|
TSAT at 6 months
|
199
|
12.1(7.89–15.9)
|
−2.36
|
204
|
10.9(7.9–15.45)
|
−2.10
|
−0.26(−1.89–1.36)
|
|
TSAT at 12 months
|
189
|
7.9(5.9–13.3)
|
201
|
8.1(5.8–11.7)
|
|
Change in 25-Hydroxy vitamin D (25-OH-D) levels, ng/ml
|
|
25 OH D at 6 months
|
199
|
20.4(13.7–29)
|
1.46
|
204
|
20.85(12–30.05)
|
−0.18
|
1.63(− 0.52–3.78)d
|
|
25OH D at 12 months
|
189
|
23.7(17.6–30.4)
|
201
|
21.80(16.9–27.9)
|
- aValues expressed as Mean+/−SD for parametric data and median (interquartile range) for nonparametric data; bParameters adjusted for compliance to the intervention, concomitant administration of iron and vitamin D supplements; cp = 0.043, d = 0.049; e-Subgroup analysis additionally adjusted for gender, weaning age and maternal education, LMF oil Liposomal encapsulated micronutrient fortified oil
